Maintenance of absolute Psoriasis Area and Severity Index (PASI) responses with guselkumab, an antiinterleukin-23p19 monoclonal antibody, through 5 years (week 252) in patients who achieved absolute PASI <= 2 at week 16 in the VOYAGE 1 study

BRITISH JOURNAL OF DERMATOLOGY(2022)

引用 0|浏览21
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要